GeoVax Labs’ (GOVX) Buy Rating Reiterated at D. Boral Capital

Posted by Editorial Team on Mar 29th, 2025

D. Boral Capital reaffirmed their buy rating on shares of GeoVax Labs (NASDAQ:GOVX – Free Report) in a research report report published on Friday,Benzinga reports. D. Boral Capital currently has a $18.00 target price on the stock.

GeoVax Labs Stock Down 12.6 %

NASDAQ:GOVX opened at $1.11 on Friday. GeoVax Labs has a 52 week low of $1.09 and a 52 week high of $11.18. The stock has a 50 day moving average of $1.67 and a 200-day moving average of $2.14.

GeoVax Labs (NASDAQ:GOVX – Get Free Report) last issued its earnings results on Thursday, March 27th. The company reported ($0.30) earnings per share for the quarter, topping the consensus estimate of ($0.79) by $0.49. The company had revenue of $3.00 million during the quarter, compared to analyst estimates of $2.38 million. As a group, sell-side analysts anticipate that GeoVax Labs will post -4.49 earnings per share for the current fiscal year.

Institutional Investors Weigh In On GeoVax Labs

Several large investors have recently made changes to their positions in GOVX. Northern Trust Corp acquired a new position in shares of GeoVax Labs during the fourth quarter worth approximately $29,000. Geode Capital Management LLC increased its position in GeoVax Labs by 59.0% in the 4th quarter. Geode Capital Management LLC now owns 90,139 shares of the company’s stock valued at $223,000 after acquiring an additional 33,440 shares during the period. Virtu Financial LLC bought a new stake in GeoVax Labs during the 3rd quarter valued at $97,000. Finally, Citadel Advisors LLC acquired a new position in GeoVax Labs during the 4th quarter worth $104,000. Institutional investors and hedge funds own 6.09% of the company’s stock.

GeoVax Labs Company Profile

(Get Free Report)

GeoVax Labs, Inc, a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using modified vaccinia ankara virus-like particle vaccine platform. It is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers.